Women’s Health

   Clear Filter
Nov 16, 2020

New Alliance to Address Multiple Pain Points for Women Living with Endometriosis

Washington, D.C., Nov. 16, 2020 (PR NEWSWIRE) – Today, seven women’s health-focused organizations – the American College of Obstetricians and Gynecologists (ACOG), the Endometriosis Association, AbbVie, HealthyWomen, the International Pelvic Pain Society (IPPS), GE Healthcare and Black Women’s Health Imperative (BWHI) – announced the formation of the Alliance for Endometriosis to improve the lives of the one in 10 women of reproductive age living with this disease in the United States.
May 29, 2020

FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women

NORTH CHICAGO, Ill., May 29, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), announced that the U.S. Food and Drug Administration (FDA) approved ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), with a treatment duration of up to 24 months.2 ORIAHNN is the first FDA-approved non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.2 ORIAHNN is expected to be available in the U.S. by the end of June 2020.